Hepatic Function Monitoring for Medications

General Principles

• The frequency of hepatic function monitoring should be based on the medication's risk profile and patient-specific factors, according to the American Association for the Study of Liver Diseases 1, 2

Medications Requiring Regular Hepatic Monitoring

• Methotrexate requires regular liver function tests every 3-6 months, with more intensive monitoring for patients with risk factors for hepatotoxicity, as recommended by the American Academy of Dermatology 3
• Isoniazid requires baseline and periodic monitoring, especially in patients with risk factors for liver disease, according to the American Thoracic Society 4, 5
• Certain antivirals for hepatitis B require monitoring every 2-6 months depending on disease severity, as suggested by the European Association for the Study of the Liver 1, 6

Monitoring Recommendations for Immunomodulatory Therapies

• For patients on immunosuppressive therapies, hepatic monitoring is primarily indicated in specific situations, such as when using medications with known hepatotoxic potential, as recommended by the European League Against Rheumatism 3, 5
• Screening for hepatitis B is recommended before starting immunosuppressive therapies, according to the European League Against Rheumatism 5, 8
• Periodic monitoring of HBV DNA and liver function tests is recommended for patients with evidence of past or current HBV infection who are on immunosuppressive therapy, as suggested by the European League Against Rheumatism 5, 8

When to Consider Hepatic Monitoring

• Baseline liver function tests may be appropriate before starting any immunosuppressive therapy, according to the Lancet Gastroenterology and Hepatology 7, 5
• Regular monitoring is indicated for patients with pre-existing liver disease, as recommended by the American Association for the Study of Liver Diseases 1, 6